The case for & against
Bull & Bear analysis
Bullish
Charles River Associates (NASDAQ: CRAI) is a leading global consulting firm specializing in economics, finance, and strategy across various industries. It enjoys a robust market position, leveraging a broad portfolio of practices that are increasingly in demand due to the growing complexity of regulatory environments, particularly in antitrust and corporate strategy. CRAI is capitalizing on significant trends in areas like life sciences and energy, making it a pivotal player in a market characterized by rapid growth and heightened consultancy needs.
Bull says
- ↑Q2 revenue $210.8M up 12.8% YoY, highest quarterly total.
- ↑Raised full-year guidance to $805–820M on strong consulting demand.
- ↑Returned $31.4M to shareholders via buybacks and dividends (1.29% yield).
- ↑Trades at 21x P/E vs fair 16.8x, suggesting ~35% undervaluation.
- ↑High earnings yield and strong balance sheet quality bolster stability.
- ↑Regulatory complexity and growth in life sciences/energy drive demand.
Bear says
- ↓Talent cost inflation and elevated receivables pressure operating margins.
- ↓Profitability metrics remain weak, raising concerns about sustainable earnings.
- ↓Premium 21x P/E vs 16.8x fair value risks sharp re-rating.
- ↓High short interest and negative momentum signal market skepticism.
- ↓Overreliance on stable regulatory and economic conditions adds vulnerability.
- ↓AI advancements and rising rates could intensify competition and pricing pressure.
Earnings Call · Q1 2024 · Mgmt. Guidance
Updated 05-04-2025neutral
Transcript signals
Bull points
- The flow of opportunities that we are seeing continues to be very, very healthy, built on a backdrop of our strong performance. That has been observed and recognized by some of our competitors and their practitioners who are thinking about making changes. CRA is seen as a very attractive destination for those top talent providers in our areas of expertise.
- The flow of opportunities that we are seeing continues to be very, very healthy, built on a backdrop of our strong performance. That has been observed and recognized by some of our competitors and their practitioners who are thinking about making changes. CRA is seen as a very attractive destination for those top talent providers in our areas of expertise.
- During the first quarter, revenue increased by 12.4% to $171.8 million, which represents the highest quarterly revenue in the company's history.
Bear points
- we ended fiscal 2023 with an overall company utilization of 70%, which was significantly lower than our targeted range of mid-70s.
- There's always a bit of tightening of the belt maybe in some of the pharmaceutical companies, but that's really it in terms of things that are directly impacting CRA.
- And when we are getting lower conversion rates, it's a bit of a surprise.
Read full transcript analysis ›